GoodRx Holdings, Inc. GDRX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- GoodRx Holdings, Inc. (GDRX) reported total cash, cash equivalents, and restricted cash (inclusive) of $235.71M in Q1 2026.
- How has GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) decreased by 21.7% year-over-year, from $300.98M to $235.71M.
- What is the long-term trend for GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a -27.4% compound annual growth rate (CAGR), from $941.11M to $261.82M.